

Amendment to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the application.

Claims 1-9 (cancelled).

10. (Previously Presented) A method for the treatment of an ocular disorder comprising administering an octreotide to a patient, wherein said octreotide binds to at least one somatostatin receptor in the eye, and wherein said ocular disorder is selected from the group consisting of retinal edema, macular edema, age related macular degeneration and central serous chorio-retinopathy.

11. (Previously Presented) The method of Claim 10, wherein said octreotide is administered topically.

12. (Previously Presented) The method of Claim 11, wherein said octreotide is administered in the form of an ophthalmic liquid preparation.

13. (Previously Presented) The method of Claim 10, wherein said octreotide is administered subcutaneously.

14. (Previously Presented) A method for the topical treatment of macular edema comprising topically administering to a patient a somatostatin analog which binds to at least one somatostatin receptor in the eye, wherein said somatostatin analog is a polypeptide, and wherein said somatostatin analog is in the form of an ophthalmic liquid preparation.

15. (Previously Presented) The method of Claim 14, wherein said ophthalmic liquid preparation is in the form of eye drops, an eye gel or an eye ointment.

16. (Previously Presented) The method of Claim 14, wherein said somatostatin receptor is an hSST-2 receptor.

17. (Previously Presented) The method of Claim 14 wherein the somatostatin analog is an octreotide.

18. (Previously Presented) A method for the topical treatment of diabetic retinopathy comprising topically administering to a patient an octreotide, wherein the octreotide binds to at least one somatostatin receptor in the eye, and wherein the octreotide is in the form of an ophthalmic liquid preparation.

19. (New) A method according to Claim 13 wherein said octreotide is administered in a dosage range of about 100 μ g to 10 mg.

20. (New) A method for the treatment of an ocular disorder comprising administering a pharmaceutical composition that consists essentially of octreotide, wherein said octreotide binds to at least one somatostatin receptor in the eye, and wherein said ocular disorder is selected from the group consisting of retinal edema, macular edema, age related macular degeneration and central serous chorio-retinopathy.